- Home
- Our Research
- Clinical Trials
- Search Clinical Trials
- Home
- Our Research
- Clinical Trials
- Search Clinical Trials
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Safiya Joseph
Phone: 203.308.8567
This is a non-inferiority randomized phase II trial investigating the efficacy and safety of 5FU/LV in combination with regorafenib for patients with metastatic colorectal cancer in the third-line setting.... Read more >
Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Safiya Joseph
Phone: 203.308.8567
The purpose of this study is to assess the safety and efficacy of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child... Read more >
Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Safiya Joseph
Phone: 203.308.8567
The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also evalu... Read more >
Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Beatriz Efron
Phone: 713.363.8890
This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for dise... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Elsie Rizk
Phone: 713.441.2557
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolizatio... Read more >
Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Elsie Rizk
Phone: 713.441.2557
We propose a regimen of six months neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria. Clinical, outcomes, an... Read more >